- Home
- CSGP vs ARGX Comparison
CSGP vs ARGX Comparison
Compare CSGP & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSGP
- ARGX
- Stock Information
- Founded
- CSGP 1987
- ARGX 2008
- Country
- CSGP United States
- ARGX Netherlands
- Employees
- CSGP N/A
- ARGX N/A
- Industry
- CSGP Business Services
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CSGP Consumer Discretionary
- ARGX Health Care
- Exchange
- CSGP Nasdaq
- ARGX Nasdaq
- Market Cap
- CSGP 31.8B
- ARGX 40.4B
- IPO Year
- CSGP 1998
- ARGX 2017
- Fundamental
- Price
- CSGP $79.91
- ARGX $571.00
- Analyst Decision
- CSGP Buy
- ARGX Strong Buy
- Analyst Count
- CSGP 15
- ARGX 20
- Target Price
- CSGP $87.87
- ARGX $682.00
- AVG Volume (30 Days)
- CSGP 4.4M
- ARGX 271.9K
- Earning Date
- CSGP 04-22-2025
- ARGX 05-08-2025
- Dividend Yield
- CSGP N/A
- ARGX N/A
- EPS Growth
- CSGP N/A
- ARGX N/A
- EPS
- CSGP 0.34
- ARGX 12.78
- Revenue
- CSGP $2,736,200,000.00
- ARGX $2,252,039,000.00
- Revenue This Year
- CSGP $12.60
- ARGX $57.59
- Revenue Next Year
- CSGP $13.05
- ARGX $31.90
- P/E Ratio
- CSGP $234.44
- ARGX $43.98
- Revenue Growth
- CSGP 11.45
- ARGX 77.52
- 52 Week Low
- CSGP $68.26
- ARGX $349.86
- 52 Week High
- CSGP $100.38
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- CSGP 61.09
- ARGX 26.36
- Support Level
- CSGP $75.79
- ARGX $618.21
- Resistance Level
- CSGP $77.35
- ARGX $642.24
- Average True Range (ATR)
- CSGP 2.64
- ARGX 15.96
- MACD
- CSGP 0.25
- ARGX -5.58
- Stochastic Oscillator
- CSGP 70.37
- ARGX 4.08
About CSGP CoStar Group Inc.
CoStar Group is a leading provider of commercial real estate data and marketplace listing platforms. Its data offering contains in-depth analytical information on over 5 million commercial real estate properties related to various subsectors including office, retail, hotels, multifamily, healthcare, industrial, self-storage, and data centers. It operates many flagship brands such as CoStar Suite, LoopNet, Apartments.com, BizBuySell, and Lands of America, with more than 80% of its revenue classified as subscription-based. The company recently expanded its presence in Canada, the United Kingdom, Spain, and France.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.